FDA Approved: ENHERTU — Supplemental Application (Daiichi Sankyo Inc.)

View source ↗

Summary

FDA approved a supplemental application for ENHERTU (fam-trastuzumab deruxtecan-nxki) from Daiichi Sankyo Inc. to update labeling and/or add indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

SUPPL AP for ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI)